Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Selectis Health (GBCS) EBIT Margin (2017 - 2025)

Selectis Health's EBIT Margin history spans 14 years, with the latest figure at 2.74% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 896.0% year-over-year to 2.74%; the TTM value through Sep 2025 reached 3.0%, up 1169.0%, while the annual FY2024 figure was 6.91%, 1745.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 2.74% at Selectis Health, up from 4.31% in the prior quarter.
  • Across five years, EBIT Margin topped out at 11.53% in Q2 2022 and bottomed at 32.53% in Q4 2023.
  • The 5-year median for EBIT Margin is 7.33% (2024), against an average of 7.73%.
  • The largest annual shift saw EBIT Margin plummeted -3216bps in 2021 before it skyrocketed 3159bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 11.4% in 2021, then decreased by -16bps to 13.27% in 2022, then crashed by -145bps to 32.53% in 2023, then surged by 97bps to 0.94% in 2024, then tumbled by -193bps to 2.74% in 2025.
  • Per Business Quant, the three most recent readings for GBCS's EBIT Margin are 2.74% (Q3 2025), 4.31% (Q2 2025), and 4.02% (Q1 2025).